Skip to main content
SpringerLink
Log in
Book cover

Peptides in Oncology I

LH-RH Agonists and Antagonists

  • Book
  • © 1992

Overview

Editors:
  1. K. Höffken

    1. Innere Klinik und Poliklinik (Tumorforschung), Universitätsklinikum Essen, Essen, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Recent Results in Cancer Research (RECENTCANCER, volume 124)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (11 chapters)

  1. Front Matter

    Pages I-XI
    Download chapter PDF

  2. Mechanisms of Action of LH-RH Agonists

    1. Gonadotropin-Releasing Hormone: Physiological and Endocrinological Aspects

      • D. Klingmüller, H. U. Schweikert
      Pages 1-6

    2. Direct Antitumor Effects of LH-RH Analogs

      • J. A. Foekens, J. G. M. Klijn
      Pages 7-17

  3. LH-RH Agonists in Benign and Malignant Tumors

    1. Treatment of Uterine Leiomyomata by LH-RH Agonists

      • Z. Blumenfeld
      Pages 19-31

    2. On the Management of Metastatic Prostate Cancer with LH-RH Analogs

      • J. H. M. Blom, F. H. Schröder
      Pages 33-41

    3. Combination Therapy with Flutamide and Castration (Orchiectomy or LH-RH Agonist) in Untreated Patients with Advanced Prostate Cancer

      • A. Dupont, F. Labrie, L. Cusan, J. L. Gomez, M. Tremblay, Y. Lacourcière et al.
      Pages 43-54

    4. LH-RH Agonists in the Treatment of Ovarian Cancer

      • G. Emons, O. Ortmann, G. S. Pahwa, F. Oberheuser, K.-D. Schulz
      Pages 55-68

    5. Treatment of Endometrial Cancer with GnRH Analogs

      • S. Kullander
      Pages 69-73

    6. LH-RH Agonists in the Treatment of Metastatic Breast Cancer: Ten Years’ Experience

      • J. G. M. Klijn
      Pages 75-90

    7. LH-RH Agonists in the Treatment of Premenopausal Patients with Advanced Breast Cancer

      • K. Höffken
      Pages 91-104

    8. LH-RH Agonists in the Treatment of Pancreatic Cancer

      • D. Gonzalez-Barcena
      Pages 105-112

  4. LH-RH Antagonists

    1. LH-RH Antagonists: State of the Art and Future Perspectives

      • G. F. Weinbauer, E. Nieschlag
      Pages 113-136

  5. Back Matter

    Pages 137-141
    Download chapter PDF
Back to top

Keywords

About this book

Hormonal treatment of malignant diseases has been used for quite some years now, and progress in this field is still being made at a steady pace. The detection of new endocrine feed­ back loops and the availability of new classes of hormonal agents made hormonal intervention with predictable outcome possible. Besides the intellectual challenge of modulating the hormone system, an important aspect of recent research on hormones and cancer is the reduction of treatment-related morbidity achieved with the new hormonal strategies. Thus, controlled intervention in the hypothalamic-gonadotropic axis is increasingly apt to replace surgical removal of the relevant glands, i. e. , the pituitary gland or the gonads. In the same way as, for example, aromatase inhibitors are being used as a substitute for adrenalectomy. The concept that secretion of hypothalamic gonadotropin­ releasing hormone (GnRH), pituitary gonadotropins, and sex steroids are regulated via negative and positive feedback loops is based on the pioneering work of Hohlweg and Harris some 40 years ago. In 1971, a breakthrough was achieved with the isolation, structural analysis, and synthesis of the luteinizing hormone releasing hormone (LH-RH), or GnRH as it is now more appropriately termed, since it provokes the secretion of both gonadotropins, LH and FSH, and since then the progress made in this area of research has been remarkable. Both ago­ nists and antagonists of LH-RH have been synthesized and extensively studied in preclinical and clinical settings.

Editors and Affiliations

  • Innere Klinik und Poliklinik (Tumorforschung), Universitätsklinikum Essen, Essen, Germany

    K. Höffken

Bibliographic Information

  • Book Title: Peptides in Oncology I

  • Book Subtitle: LH-RH Agonists and Antagonists

  • Editors: K. Höffken

  • Series Title: Recent Results in Cancer Research

  • DOI: https://doi.org/10.1007/978-88-470-2186-0

  • Publisher: Springer Milano

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer-Verlag Berlin Heidelberg 1992

  • Softcover ISBN: 978-88-470-2188-4Published: 21 December 2011

  • eBook ISBN: 978-88-470-2186-0Published: 06 December 2012

  • Series ISSN: 0080-0015

  • Series E-ISSN: 2197-6767

  • Edition Number: 1

  • Number of Pages: XII, 141

  • Number of Illustrations: 6 b/w illustrations

  • Topics: Oncology

Publish with us

Policies and ethics

Back to top

Search

Navigation